The Food and Drug Administration (FDA) recently approved extending the dosing interval Eylea HD 8 mg for up to every 20 weeks for wet macular degeneration and diabetic macular edema patients (DME).
This updated dosing schedule means that wet AMD and DME patients can now have their treatment plans tailored to their individual needs. The change was brought about by the results from the PULSAR and PHOTON trials. Most individuals in those trials who completed 2 years, were able to maintain or push out dosing intervals and still maintain current visual improvements.
Side effects associated with Eylea HD patients include cataracts, retinal hemorrhage, blurred vision, increased intraocular pressure among other things.
